5 Biotech Stocks in Billionaire Ray Dalio’s Portfolio

Page 1 of 5

In this piece, we will take a look at the 5 biotech stocks in billionaire Ray Dalio’s portfolio. If you want more details about Mr. Dalio, his fund and other stocks then take a look at 10 Biotech Stocks in Billionaire Ray Dalio’s Portfolio.

5. NovoCure Limited (NASDAQ:NVCR)

Bridgewater Associates’ Stake Value: $11.1 million

Percentage of Bridgewater Associates’ 13F Portfolio: 0.06%

Number of Hedge Fund Holders: 23

Closing price on December 10, 2021: $84.25

NovoCure Limited (NASDAQ:NVCR) is an American company that deals in providing treatments for several kinds of tumors. Its Optune lineup targets brain cancer, and it is also working on products to target others cancers such as those of the lungs, pancreas, and liver.

Mr. Dalio’s investment firm held 96,106 NovoCure Limited (NASDAQ:NVCR) shares during this year’s third quarter. These were worth $11.1 million and represented 0.06% of its portfolio. During Q3 2021, 23 of the 867 hedge funds polled by Insider Monkey owned the company’s shares.

NovoCure Limited (NASDAQ:NVCR) missed analyst estimates for revenue and GAAP EPS in its Q3, by posting $133 million in revenue and -$0.13 in GAAP EPS. Its price target was lowered to $180 from $195 by Piper Sandler in an October 2021 analyst note which outlined that the Q3 results were the third time the company had disappointed Wall Street and clinical slippages for a product were not positive either.

NovoCure Limited (NASDAQ:NVCR)’s largest shareholder is Anand Desai’s Darsana Capital Partners. It owns 700,000 shares worth $81 million.


Page 1 of 5